Experimental group:Tislelizumab

7 trials

Conditions

Breast cancerNon-small cell lung cancerNon-small-cell lung cancerOral leukoplakia and oral erythemaUpper Tract Urothelial Carcinoma (UTUC)non-small cell lung cancer (NSCLC)nonsmall-cell lung cancer

Early Phase 1

Application and demonstration of tislelizumab in adjuvant treatment of stage II-IIIA NSCLC

Active, not recruitingChiCTR2200060484

Affiliated Hospital of Zunyi Medical Universitynon-small cell lung cancer (NSCLC)

Start: 2022-06-01Updated: 2024-05-21

Phase 2

Neoadjuvant Phase II Study of Tislelizumab combined with chemotherapy in Triple Negative Breast Cancer

Active, not recruitingChiCTR2000035262

Liaoning Province Cancer HospitalBreast cancer

Start: 2020-08-31Updated: 2020-08-10

A phase II clinical trial of chemotherapy combined with Tislelizumab neoadjuvant therapy for resectable stage IIIA lung squamous cell carcinoma and exploration of related biomarkers

Active, not recruitingChiCTR2200058785

Cancer Hospital Chinese Academy of Medical SciencesNon-small cell lung cancer

Start: 2022-04-17Updated: 2024-01-22

A prospective, open-label, single-arm, phase II trial investigating the efficacy and safety of Tislelizumab consolidation therapy after radiotherapy or sequential chemoradiotherapy in locally advanced non-small-cell lung cancer patients who are intolerable of concurrent concurrent chemoradiotherapy

RecruitingChiCTR2200063476

Peking University Cancer HospitalNon-small-cell lung cancer

Start: 2022-09-01Updated: 2023-04-17

Unknown Phase

Effect of neoadjuvant anti-PD-1 monoclonal antibody treatment on perioperative analgesia and POD in patients with non-small cell lung cancer surgery

RecruitingChiCTR2100041934

Tianjin Medical University Cancer Institute and Hospitalnonsmall-cell lung cancer

Start: 2021-01-01Updated: 2021-03-30

A single-arm, open, prospective clinical study of tislelizumab in the treatment of oral leukoplakia and oral erythema

Active, not recruitingChiCTR2500104633

West China Hospital of Sichuan UniversityOral leukoplakia and oral erythema

Start: 2025-07-01Updated: 2025-06-24

Maintenance Therapy with Tislelizumab after Postoperative Chemotherapy in Upper Tract Urothelial Carcinoma

Active, not recruitingChiCTR2500115259

The First Affiliated Hospital of Wenzhou Medical UniversityUpper Tract Urothelial Carcinoma (UTUC)

Start: 2025-12-24Updated: 2026-01-05

Related Papers

Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab (a PD-1 inhibitor) plus nab-paclitaxel followed by epirubicin/cyclophosphamide for triple-negative breast cancer: a phase 2 TREND trial.

2025-05-265 citations

Neoadjuvant tislelizumab, a PD-1 mAb plus nab-paclitaxel (nab-P) followed by tislelizumab plus epirubicin/cyclophosphamide (EC) for triple-negative breast cancers (TNBC): Interim analysis of clinical response in a phase 2 TREND trial.